加拿大允许通用Ozempic自2026年1月4日开始,降低糖尿病和肥胖病人的费用。 Canada allows generic Ozempic starting Jan. 4, 2026, lowering costs for diabetes and obesity patients.

从2026年1月4日起, 加拿大在诺沃·诺迪斯克的专利过期后, 允许使用含有微粒的Ozempic的通用版本Ozempic, 这是唯一出现这种情况的国家。 Starting January 4, 2026, Canada allows generic versions of Ozempic, containing semaglutide, after Novo Nordisk’s patent expired—the only country where this occurred. 加拿大卫生部收到了包括Sandoz、Apotex和Teva公司在内的公司提出的九份一般微硫化物申请,但由于审查过程复杂,预计不会在春末或夏初之前获得批准。 Health Canada has received nine applications for generic semaglutide from companies including Sandoz, Apotex, and Teva, but approval is not expected before late spring or early summer due to the complex review process. 通用版本的成本可能仅为品牌价格的35%,从而改善2型糖尿病和肥胖症患者的就医机会。 Generic versions could cost as little as 35% of the brand-name price, improving access for patients with Type 2 diabetes and obesity. 虽然预计非专利药物将具有等效药品,但一些病人的反应可能有所不同。 While generics are expected to be pharmaceutically equivalent, some patients may respond differently. Novo Nordisk将继续向未投保的病人提供财政支持。 Novo Nordisk will continue offering financial support for uninsured patients. Eli Lilly的竞争药物在加拿大仍受专利保护。 Eli Lilly’s competing drugs remain under patent protection in Canada.